IMCR Stock Overview
A commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Immunocore Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28.66 |
| 52 Week High | US$76.98 |
| 52 Week Low | US$27.69 |
| Beta | 0.73 |
| 1 Month Change | -11.68% |
| 3 Month Change | -8.73% |
| 1 Year Change | -58.21% |
| 3 Year Change | -15.95% |
| 5 Year Change | n/a |
| Change since IPO | -33.66% |
Recent News & Updates
Recent updates
Immunocore Is Adequately Valued, But Its Prospects Are Uncertain
Dec 10Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Oct 24
Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry
Sep 19Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal
Aug 12Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?
Jul 24Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues
Jun 16Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
May 11Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 11Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?
Apr 05Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money
Jan 22Immunocore Holdings: Vulnerable To Profit Taking After Big Rally
Jan 21Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%
Dec 18Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S
May 08Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically
Nov 16Immunocore: Attractive Commercial-Stage Biopharma
Oct 05Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)
Aug 12Immunocore GAAP EPS of -$0.17, revenue of $38.92M
Aug 10Immunocore to raise $140M in private placement financing
Jul 18Shareholder Returns
| IMCR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.8% | -3.3% | -0.4% |
| 1Y | -58.2% | -2.7% | 24.8% |
Return vs Industry: IMCR underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: IMCR underperformed the US Market which returned 24.8% over the past year.
Price Volatility
| IMCR volatility | |
|---|---|
| IMCR Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IMCR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IMCR's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 497 | Bahija Jallal | www.immunocore.com |
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Immunocore Holdings plc Fundamentals Summary
| IMCR fundamental statistics | |
|---|---|
| Market cap | US$1.43b |
| Earnings (TTM) | -US$47.05m |
| Revenue (TTM) | US$296.31m |
4.8x
P/S Ratio-30.5x
P/E RatioIs IMCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMCR income statement (TTM) | |
|---|---|
| Revenue | US$296.31m |
| Cost of Revenue | US$208.75m |
| Gross Profit | US$87.56m |
| Other Expenses | US$134.61m |
| Earnings | -US$47.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | 29.55% |
| Net Profit Margin | -15.88% |
| Debt/Equity Ratio | 116.1% |
How did IMCR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:10 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Immunocore Holdings plc is covered by 22 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Peter Lawson | Barclays |
| Olga Smolentseva | Bryan Garnier & Co |